AI-generated analysis. Always verify with the original filing.
Azitra, Inc. announced financial results for the full year ended December 31, 2025, reporting a net loss of $11.0 million compared to $9.0 million in the prior year. The company ended the period with $2.1 million in cash and equivalents, while highlighting progress in its ATR-12, ATR-04, and ATR-01 clinical programs.
Event Type
Disclosure
Mandatory
Variant
8-K
, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 but shall not be deemed “filed” for any purpose, including for
Financial Statements and Exhibits (d): The following exhibits are being filed electronically herewith: Exhibit No. Description 99.1 Press release dated February
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $0.00 | |
| Research and Development Expenses | $4.80 | GAAP |
| General and Administrative Expenses | $6.20 | GAAP |
| Net Loss | $11.00 | GAAP |
| Net Loss Per Share, Basic and Diluted | $-2.25 | GAAP |